Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Next Previous
Trial Profile

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adagrasib (Primary) ; Afatinib (Primary) ; Cetuximab (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Appendiceal cancer; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept; Registrational; Therapeutic Use
  • Acronyms KRYSTAL; KRYSTAL-01; KRYSTAL-1
  • Sponsors Mirati Therapeutics

Most Recent Events

  • 17 Jul 2025 Planned End Date changed from 16 Jan 2026 to 31 Dec 2026.
  • 17 Jul 2025 Planned primary completion date changed from 14 Jul 2025 to 31 Dec 2026.
  • 30 Apr 2025 Results(n=35) evaluating safety, tolerability and pharmacokinetics of MRTX849 (Adagrasib) in patients with advanced solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top